We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Epistem | EHP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 85.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 85.00 | 85.00 |
| Top Posts |
|---|
Posted at 29/7/2016 09:21 by the ghost who walks Wondering if the new website will have upgraded investor relations disclosures. Closely watching. |
Posted at 26/10/2015 09:01 by azzi No longer an investor, but still keep watching. If all was OK with the technology we should have received an update following the Indian launch by now. I still think something is fundamentally wrong with the technology, if so, I think investors past and present deserve some honest messaging. |
Posted at 14/8/2015 08:21 by azzi Ghost - Well to start with Luminex/Cepheid and GenXpert, these received WHO approval for Tb in 2010. Simply search "GeneXpert MTB/RIF" in Wikipedia for starters - I assume all investors conduct such searches as a matter of routine.You will see that it is a direct competitor to EHP - sure there are differences but their technology has been in the market for nearly 5 years already - there is nothing novel about MTB/RIF testing! Once you have researched some of the valuable references cited, take a look at the WHO site and search under TB and you will find many more companies playing in the same field - it should be an eye opener. |
Posted at 01/5/2015 10:32 by aim_trader Matthew Walls, CEO of Epistem, will be updating investors in London on the 14th May. Register to attend here: |
Posted at 24/4/2015 13:35 by proactivest Video interview with CEO Matthew WallsMatthew Walls, chief executive of Epistem (Lon:EHP), says distribution of its handheld TB diagnostic device in India paves the way for other distributor-based deals globally. Walls tells Proactive Investors the test market for TB will be worth US$2bln by 2020, and the biotechnology company’s signature Genedrive tool lends itself to testing all bacterial, viral, fungal and somatic mutations of the body. Described as 'breakthrough next generation technology' Genedrive is gathering more commercial exposure and Walls says more funds may be required over the next few months to accelerate the device’s push into the global marketplace. |
Posted at 26/10/2014 19:37 by azzi There must be some problem as EHP should be well on track to deliver on their promise to launch the Genedrive Tb technology by the end of this year?Bigman you are correct, I hold 2 AIM biotechs which I always say are for entertainment. The truth is I also want to make money out of them. I guess I am just fascinated to follow the psychology of AIM companies - this primarily relates to the directors. It appears to me AIM is a mechanism for some brass necked individuals free of any morals and ethics to freely spend the money of their investors whilst keeping price sensitive info very close to their chest. So I say - time to come clean Epistem - you've talked the talk...... Azzi |
Posted at 04/8/2014 21:38 by azzi I was an investor hear quite a few years ago and made a fair paper profit which evaporated last Autumn. I sold out but foolishly I re-invested as I believed in Genedrive etc, unfortunately I am increasingly suspicious that not all is going to plan with the technology, the Indian TB launch was scheduled for the second half of this year but there appears to be no progress update to ease my worries.I'll stick with it for another month or two, however I agree with bigman - all promises and nothing delivered. Yet another AIM company where the directors are fattening themselves upon the investors money....sorry to be so cynical and negative. Az |
Posted at 25/3/2014 11:12 by azzi Well I think all Epistems eggs are in one basket now, this is a much higher risk play than the co. I invested in 5 years ago. Genedrive quite simply HAS to deliver in a massive way! Will be watching very, very closely - no further delay will be acceptable to investors. |
Posted at 29/12/2013 19:41 by azzi Hmmm..I remain perplexed. The recent announcement re- US military evaluation and FIND initiative should have given an upward push for the share price It seems the Genedrive system is now the key focus of attention for EPH, what has happened to all the other ground backing technologies? The launch of the first genedrive test had better not be delayed - I still feel we are not aware of the full picture here, is the genedrive system really that good? BD walked away from it , right or wrong? I am a confused long term ex-investor, however I would consider re-investing if I believe the story. |
Posted at 02/10/2013 22:09 by azzi Just as an update - I held onto 25% of my holding "in the hope" of a bullish update this evening. So with a declining share price and failure to take the opportunity to update investors this evening, I will now be offloading the remainder of my holding. What a shame!! |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
